Integrative radiomics and transcriptomics analyses reveal subtype characterization of non-small cell lung cancer
- PMID: 36826501
- DOI: 10.1007/s00330-023-09503-5
Integrative radiomics and transcriptomics analyses reveal subtype characterization of non-small cell lung cancer
Abstract
Objectives: To assess whether integrative radiomics and transcriptomics analyses could provide novel insights for radiomic features' molecular annotation and effective risk stratification in non-small cell lung cancer (NSCLC).
Methods: A total of 627 NSCLC patients from three datasets were included. Radiomics features were extracted from segmented 3-dimensional tumour volumes and were z-score normalized for further analysis. In transcriptomics level, 186 pathways and 28 types of immune cells were assessed by using the Gene Set Variation Analysis (GSVA) algorithm. NSCLC patients were categorized into subgroups based on their radiomic features and pathways enrichment scores using consensus clustering. Subgroup-specific radiomics features were used to validate clustering performance and prognostic value. Kaplan-Meier survival analysis with the log-rank test and univariable and multivariable Cox analyses were conducted to explore survival differences among the subgroups.
Results: Three radiotranscriptomics subtypes (RTSs) were identified based on the radiomics and pathways enrichment profiles. The three RTSs were characterized as having specific molecular hallmarks: RTS1 (proliferation subtype), RTS2 (metabolism subtype), and RTS3 (immune activation subtype). RTS3 showed increased infiltration of most immune cells. The RTS stratification strategy was validated in a validation cohort and showed significant prognostic value. Survival analysis demonstrated that the RTS strategy could stratify NSCLC patients according to prognosis (p = 0.009), and the RTS strategy remained an independent prognostic indicator after adjusting for other clinical parameters.
Conclusions: This radiotranscriptomics study provides a stratification strategy for NSCLC that could provide information for radiomics feature molecular annotation and prognostic prediction.
Key points: • Radiotranscriptomics subtypes (RTSs) could be used to stratify molecularly heterogeneous patients. • RTSs showed relationships between molecular phenotypes and radiomics features. • The RTS algorithm could be used to identify patients with poor prognosis.
Keywords: Heterogeneity; Non-small cell lung cancer; Radiomics; Transcriptomics.
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Similar articles
-
Impact of feature selection methods and subgroup factors on prognostic analysis with CT-based radiomics in non-small cell lung cancer patients.Radiat Oncol. 2021 Apr 30;16(1):80. doi: 10.1186/s13014-021-01810-9. Radiat Oncol. 2021. PMID: 33931085 Free PMC article.
-
Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.J Cancer Res Clin Oncol. 2024 Oct 10;150(10):453. doi: 10.1007/s00432-024-05971-4. J Cancer Res Clin Oncol. 2024. PMID: 39387925 Free PMC article.
-
Synergies of Radiomics and Transcriptomics in Lung Cancer Diagnosis: A Pilot Study.Diagnostics (Basel). 2023 Feb 15;13(4):738. doi: 10.3390/diagnostics13040738. Diagnostics (Basel). 2023. PMID: 36832225 Free PMC article.
-
Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review.Br J Radiol. 2021 Jun 1;94(1122):20201272. doi: 10.1259/bjr.20201272. Epub 2021 May 12. Br J Radiol. 2021. PMID: 33882244 Free PMC article.
-
Radiomics features as predictive and prognostic biomarkers in NSCLC.Expert Rev Anticancer Ther. 2021 Mar;21(3):257-266. doi: 10.1080/14737140.2021.1852935. Epub 2020 Dec 4. Expert Rev Anticancer Ther. 2021. PMID: 33216651 Review.
Cited by
-
CT-based radiomic consensus clustering association with tumor biological behavior in clinical stage IA adenocarcinoma: a retrospective study.Transl Lung Cancer Res. 2024 Aug 31;13(8):1794-1806. doi: 10.21037/tlcr-24-283. Epub 2024 Aug 12. Transl Lung Cancer Res. 2024. PMID: 39263010 Free PMC article.
-
Development and validation of a contrast-enhanced CT-based radiomics nomogram for preoperative diagnosis in neuroendocrine carcinoma of digestive system.Front Endocrinol (Lausanne). 2023 Apr 12;14:1155307. doi: 10.3389/fendo.2023.1155307. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37124722 Free PMC article.
-
Incidence rate of occult lymph node metastasis in clinical T1-2N0M0 small cell lung cancer patients and radiomic prediction based on contrast-enhanced CT imaging: a multicenter study : Original research.Respir Res. 2024 May 29;25(1):226. doi: 10.1186/s12931-024-02852-9. Respir Res. 2024. PMID: 38811960 Free PMC article.
-
Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survival.Transl Lung Cancer Res. 2024 Dec 31;13(12):3303-3322. doi: 10.21037/tlcr-24-576. Epub 2024 Dec 27. Transl Lung Cancer Res. 2024. PMID: 39830771 Free PMC article.
-
Development and validation of a multi-modal ultrasomics model to predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.BMC Med Imaging. 2024 Mar 18;24(1):65. doi: 10.1186/s12880-024-01237-0. BMC Med Imaging. 2024. PMID: 38500022 Free PMC article.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical